SEP-1早期管理集束化治疗依从性对脓毒症医保受益人死亡率的影响:倾向性评分匹配队列研究
该研究基于2015年10月至2017年3月3241家医院上报Medicare的患者层面数据,采用倾向性评分匹配和分层广义线性模型评估SEP-1依从性与30天死亡率的关系。依从性定义为完成所有合格SEP-1要素,包括乳酸测量、血培养采集、广谱抗生素给药、30 mL/kg晶体液输注、血管升压药应用和患者再评估。标准匹配中依从组与非依从组各122,870例,30天死亡率21.81% vs 27.48%,ARR 5.67%(95%CI 5.33-6.00,P<.001);严格匹配中两组各107,016例,死亡率22.22% vs 26.28%,ARR 4.06%(95%CI 3.70-4.41,P<.001);受试者水平风险调整条件OR 0.829(95%CI 0.812-0.846,P<.001)。依从组中位住院时间更短(5天 vs 6天,P<.001)。
要点
- SEP-1依从性与30天死亡率降低相关:标准匹配ARR 5.67%(95%CI 5.33-6.00),严格匹配ARR 4.06%(95%CI 3.70-4.41)。
- 依从性定义为完成全部合格SEP-1要素:乳酸测量、血培养、广谱抗生素、30 mL/kg晶体液、血管升压药和再评估。
- 风险调整后依从组30天死亡风险更低(条件OR 0.829,95%CI 0.812-0.846,P<.001)。
- 依从组中位住院时间更短(5天 vs 6天,P<.001)。
- 多个SEP-1要素与死亡率降低相关(原文未列具体要素及效应值)。
适用人群与场景
- 2015年10月1日至2017年3月31日期间,3241家医院向Medicare上报的脓毒症患者(患者层面数据)。
诊断标准与关键阈值
- SEP-1依从性定义:完成所有合格SEP-1要素,包括乳酸测量、血培养采集、广谱抗生素给药、30 mL/kg晶体液输注、血管升压药应用和患者再评估。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:倾向性评分匹配队列研究,基于Medicare数据,3241家医院,患者层面数据,时间2015年10月1日至2017年3月31日。
- 标准匹配:依从组122,870例 vs 非依从组122,870例,30天死亡率21.81% vs 27.48%,ARR 5.67%(95%CI 5.33-6.00,P<.001)。
- 严格匹配:依从组107,016例 vs 非依从组107,016例,30天死亡率22.22% vs 26.28%,ARR 4.06%(95%CI 3.70-4.41,P<.001)。
- 受试者水平HGLM:依从性与较低30天风险调整死亡率相关(调整条件OR 0.829,95%CI 0.812-0.846,P<.001)。
- 依从组中位住院时间更短(5天 vs 6天,IQR 3-9 vs 4-10,P<.001)。
- 多个要素与较低死亡率相关(原文未列具体要素及效应值)。
证据类型、等级与局限
- 证据类型:倾向性评分匹配队列研究(观察性研究)。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确列出局限;设计为回顾性、基于上报数据、观察性研究,可能存在残余混杂。
对床旁实践的改变
- 该研究支持在脓毒症患者中实施SEP-1集束化治疗以提高依从性,可能降低30天死亡率。
- 原文未提及适用与不适用人群的具体标准。
指南或共识出处
- 原文未提及指南或共识名称;研究本身为基于Medicare数据的队列研究。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: US hospitals have reported compliance with the SEP-1 quality measure to Medicare since 2015. Finding an association between compliance and outcomes is essential to gauge measure effectiveness.
RESEARCH QUESTION: What is the association between compliance with SEP-1 and 30-day mortality among Medicare beneficiaries?
STUDY DESIGN AND METHODS: Studying patient-level data reported to Medicare by 3,241 hospitals from October 1, 2015, to March 31, 2017, we used propensity score matching and a hierarchical general linear model (HGLM) to estimate the treatment effects associated with compliance with SEP-1. Compliance was defined as completion of all qualifying SEP-1 elements including lactate measurements, blood culture collection, broad-spectrum antibiotic administration, 30 mL/kg crystalloid fluid administration, application of vasopressors, and patient reassessment. The primary outcome was a change in 30-day mortality. Secondary outcomes included changes in length of stay.
RESULTS: We completed two matches to evaluate population-level treatment effects. In standard match, 122,870 patients whose care was compliant were matched with the same number whose care was noncompliant. Compliance was associated with a reduction in 30-day mortality (21.81% vs 27.48%, respectively), yielding an absolute risk reduction (ARR) of 5.67% (95% CI, 5.33-6.00; P < .001). In stringent match, 107,016 patients whose care was compliant were matched with the same number whose care was noncompliant. Compliance was associated with a reduction in 30-day mortality (22.22% vs 26.28%, respectively), yielding an ARR of 4.06% (95% CI, 3.70-4.41; P < .001). At the subject level, our HGLM found compliance associated with lower 30-day risk-adjusted mortality (adjusted conditional OR, 0.829; 95% CI, 0.812-0.846; P < .001). Multiple elements correlated with lower mortality. Median length of stay was shorter among cases whose care was compliant (5 vs 6 days; interquartile range, 3-9 vs 4-10, respectively; P < .001).
INTERPRETATION: Compliance with SEP-1 was associated with lower 30-day mortality. Rendering SEP-1 compliant care may reduce the incidence of avoidable deaths.
参考来源
- Townsend SR, Phillips GS, Duseja R, et al. Effects of Compliance With the Early Management Bundle (SEP-1) on Mortality Changes Among Medicare Beneficiaries With Sepsis: A Propensity Score Matched Cohort Study. Chest. 2021. PMID: 34364867. doi:10.1016/j.chest.2021.07.2167
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。